The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines and two biosimilars ...

US drugmaker Ironwood Pharmaceuticals, which is focused on gastrointestinal and rare diseases, has announced a leadership ...

US genetic medicines developer Estuary Biotherapeutics today announced its launch with $103 million in total committed ...

Fractyl Health today announced top-line six-month results from the Pivotal Cohort of its ongoing REMAIN-1 study (Pivotal ...

Singapore based clinical-stage biotech Adlai Nortye Group has entered into clinical trial collaboration and supply agreements ...

US biotech company Iambic Therapeutics (Nasdaq: IAM) has priced a $150 million initial public offering (IPO), securing ...

Belgian biotech Lakefront Biotherapeutics (Euronext: LKFT), formerly Galapagos, has sold its preclinical cell therapy ...

Cambridge, UK based Microbiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision ...

Shares in Swedish biotech Modus Therapeutics fell by half in Stockholm trading on Thursday after the company paused ...

The US regulator, the Food and Drug Administration (FDA), has launched an initiative to reshape rare disease drug development ...

Japan’s largest drugmaker Takeda today announced that Orzeyful (oveporexton) is now available in Japan and China for the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is introducing a series of new measures to strengthen how ...